KPTI Karyopharm Therapeutics Inc.

10.7
-0.16  -1%
Previous Close 10.86
Open 10.85
Price To Book 8.04
Market Cap 662,549,532
Shares 61,920,517
Volume 875,858
Short Ratio
Av. Daily Volume 1,601,629
Stock charts supplied by TradingView

NewsSee all news

  1. Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    NEWTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors

  2. Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million

    NEWTON, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), an oncology-focused pharmaceutical company, today announced its entry into a royalty agreement with HealthCare Royalty

  3. Karyopharm Announces XPOVIO™ (Selinexor) Presentations at the 17th International Myeloma Workshop

    NEWTON, Mass., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), an oncology-focused pharmaceutical company, today announced that five abstracts highlighting clinical data for

  4. NATIONALLY RANKED ROSEN LAW FIRM Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM – KPTI

    NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds Karyopharm Therapeutics Inc. (NASDAQ:KPTI) investors who purchased securities: (i) from March 2, 2017 through

  5. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

    NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ:KPTI) of the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 updated data presented at ASH 2016.
Selinexor - SAIL
Acute myeloid leukemia (AML)
Phase 2 initiated April 2014. Interim data at ASCO 2015
Selinexor - (KING study)
Cancer - glioblastoma
Phase 3 top-line data due in 2020.
Selinexor - SEAL
Dedifferentiated liposarcoma
FDA Approval announced July 3, 2019. Continued approval may be contingent upon data from its Phase 3 Boston trial (data due late-2019/early 2020).
Selinexor
Quadruple Refractory Multiple Myeloma
Phase 3 data due end of 2019 or into 2020.
Selinexor - BOSTON
Multiple myeloma
NDA filing due 4Q 2019 or 1Q 2020.
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Data Safety Monitoring Board (DSMB) noted March 2, 2017 that trial will not meet primary endpoint.
Selinexor SOPRA
Cancer - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 2 data presented at ASCO 2015. Phase 3 trial to be initiated late 2017.
Selinexor (SIGN Study)
Cancer - Advanced Gynecologic Malignancies (SIGN Study)
Phase 2 trial terminated.
Selinexor - SIRRT
Richter's transformation
Phase 2 trial terminated.
Selinexor - SHIP
Cancer - hormone-refractory prostate cancer (HRPC)
Phase 3 enrolment to be completed 2020.
Selinexor - SIENDO
Endometrial cancer
Phase 2 data reported at ASCO-GU 2019.
Eltanexor
Solid tumors
Phase 1/2 updated tolerability data due 2019.
KPT-9274
Non-Hodgkin Lymphoma

Latest News

  1. Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    NEWTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors

  2. Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million

    NEWTON, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), an oncology-focused pharmaceutical company, today announced its entry into a royalty agreement with HealthCare Royalty

  3. Karyopharm Announces XPOVIO™ (Selinexor) Presentations at the 17th International Myeloma Workshop

    NEWTON, Mass., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), an oncology-focused pharmaceutical company, today announced that five abstracts highlighting clinical data for

  4. NATIONALLY RANKED ROSEN LAW FIRM Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM – KPTI

    NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds Karyopharm Therapeutics Inc. (NASDAQ:KPTI) investors who purchased securities: (i) from March 2, 2017 through

  5. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

    NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ:KPTI) of the

  6. CLASS ACTION UPDATE for OMCL, KPTI, CURLF and TWOU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested

  7. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of KPTI, EGBN, MNK and CAH

    CEDARHURST, N.Y., Sept. 06, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies.

  8. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ:KPTI). Such investors are advised to

  9. SHAREHOLDER ALERT: INS KPTI EGBN VAL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the

  10. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ:KPTI) of the

  11. NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC – Class Action Update

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies.

  12. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of INS, OMCL, KPTI and CAH

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the

  13. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

    New York, New York--(Newsfile Corp. - September 3, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) ("Karyopharm" or the

  14. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ideanomics, Eagle Bancorp, Karyopharm Therapeutics, and National General Holdings and Encourages Investors to Contact the Firm

    NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Ideanomics, Inc (NASDAQ:IDEX), Eagle Bancorp,

  15. CLASS ACTION UPDATE for NFLX, KPTI, GVA and CVS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested

  16. Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    NEWTON, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors

  17. Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC) - Bronstein, Gewirtz & Grossman, LLC – Class Action Update

    NEW YORK, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies.

  18. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ:KPTI). Such investors are advised to

  19. ROSEN, A TOP RANKED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action - KPTI

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds Karyopharm Therapeutics Inc. (NASDAQ:KPTI) investors who purchased securities: (i) from March 2, 2017 through

  20. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ:KPTI) of the

  21. SHAREHOLDER ALERT: LB KPTI EVH VAL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the

  22. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPTI, JE, GTT and VAL

    NEW YORK, Aug. 28, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead

  23. Karyopharm to Participate in Upcoming Investor Conferences

    NEWTON, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), an oncology-focused pharmaceutical company, announced today that the Company's management team will participate in the

  24. CLASS ACTION UPDATE for VNTR, KPTI, GTT and VAL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in

  25. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Karyopharm, L Brands, National General, and Mallinckrodt and Encourages Investors to Contact the Firm

    NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Karyopharm Therapeutics, Inc. (NASDAQ:KPTI), L

  26. Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc. – KPTI

    NEW YORK, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) from March 2, 2017

  27. INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In OMCL, DEX, NFLX or KPTI To Contact The Firm

    New York, New York--(Newsfile Corp. - August 25, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, encourages investors in the following companies to contact the firm:Company: Omnicell, Inc.

  28. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

    NEW YORK, Aug. 24, 2019 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ:KPTI). Such investors are advised to

  29. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

    NEW YORK, Aug. 24, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ:KPTI). Such investors are

  30. Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC) – Class Action Reminder – Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies.

  31. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FDX, CTST, KPTI and NGHC

    NEW YORK, Aug. 22, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead

  32. Karyopharm Announces Publication of XPOVIO™ (Selinexor) Phase 2b STORM Study Results in The New England Journal of Medicine

    -- XPOVIO was Recently Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and an Anti-CD38 Monoclonal Antibody -- -- In